1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydron;chloride
• 化学式: C33H36Cl3N5O3
• 分子量: 657.0
• InChiKey: IOTAOYHKWICOBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.25
• 重原子数：
  44
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  143
• 氢给体数：
  5
• 氢受体数：
  5

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间的使用总结：目前没有关于在母乳喂养期间使用阿托伐喹和普龙胍的信息。美国疾病控制与预防中心目前不推荐将其用于预防体重低于5公斤（11磅）婴儿的哺乳妇女的疟疾。然而，当对婴儿的潜在益处超过潜在风险时，可以用于治疗任何体重新生儿的哺乳妇女（例如，治疗在多重耐药株地区感染恶性疟疾且无法耐受其他治疗选择的哺乳妇女）。 通常情况下，哺乳妇女的乳汁中会分泌非常少量的抗疟疾药物。由于通过乳汁传递的抗疟疾药物量不足以提供对抗疟疾的充分保护，因此需要化学预防的婴儿也必须接受推荐剂量的抗疟疾药物。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the use of atovaquone and proguanil during breastfeeding. The Centers for Disease Control and Prevention does not currently recommend it for the prevention of malaria in women breastfeeding infants weighing less than 5 kg (11 pounds). However, it can be used for treatment of women who are breastfeeding infants of any weight when the potential benefit outweighs the potential risk to the infant (e.g., treating a breastfeeding woman who has acquired P. falciparum malaria in an area of multidrug-resistant strains and who cannot tolerate other treatment options). In general, very small amounts of antimalarial drugs are excreted in the breast milk of lactating women. Because the quantity of antimalarial drugs transferred in breast milk is insufficient to provide adequate protection against malaria, infants who require chemoprophylaxis must also receive the recommended dosages of antimalarial drugs. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：目前没有关于在母乳喂养期间使用阿托伐喹和普龙胍的信息。美国疾病控制与预防中心目前不推荐将其用于预防体重小于5公斤（11磅）婴儿的哺乳妇女的疟疾。然而，当对婴儿的潜在益处超过潜在风险时，可以用于治疗任何体重新生儿的哺乳妇女（例如，治疗在多药耐药株地区获得恶性疟疾且无法耐受其他治疗选择的哺乳妇女）。 通常，哺乳妇女的母乳中会分泌非常少量的抗疟疾药物。由于通过母乳转移的抗疟疾药物量不足以提供对抗疟疾的充分保护，因此需要化学预防的婴儿也必须接受推荐剂量的抗疟疾药物。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the use of atovaquone and proguanil during breastfeeding. The Centers for Disease Control and Prevention does not currently recommend it for the prevention of malaria in women breastfeeding infants weighing less than 5 kg (11 pounds). However, it can be used for treatment of women who are breastfeeding infants of any weight when the potential benefit outweighs the potential risk to the infant (e.g., treating a breastfeeding woman who has acquired P. falciparum malaria in an area of multidrug-resistant strains and who cannot tolerate other treatment options). In general, very small amounts of antimalarial drugs are excreted in the breast milk of lactating women. Because the quantity of antimalarial drugs transferred in breast milk is insufficient to provide adequate protection against malaria, infants who require chemoprophylaxis must also receive the recommended dosages of antimalarial drugs. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)